Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines

Gene Therapy

Volumn 7, Issue 24, 2000, Pages 2113-2121

  Akiyama, Y ^a   Watanabe, M ^b   Maruyama, K ^a   Ruscetti, F W ^c   Wiltrout, R H ^b   Yamaguchi, K ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b Laboratory of Experimental Immunology   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Genetically modified dendritic cells (DC); Interleukin (IL) 12; Intratumoral injection; Malignant melanoma

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL SELECTION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; SENSITIZATION; SPLEEN CELL; STEM CELL; SUPERNATANT; SURVIVAL; TUMOR IMMUNITY; TUMOR VOLUME;

ANIMALS; DENDRITIC CELLS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELLS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRALESIONAL; INTERLEUKIN-12; INTERLEUKIN-2; LUMINESCENT PROTEINS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RETROVIRIDAE; TRANSDUCTION, GENETIC;

ANIMALIA; RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 0034511315     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301353     Document Type: Article

References (37)

1. Dendritic cells and the control of immunity
2. Dendritic cells as initiators of tumor immune response: A possible strategy for tumor immunotherapy?
3. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
4. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity
5. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
6. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cell in situ
7. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity
8. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
9. CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T cell hyporesponsiveness in vitro and prevent acute allograft rejection
10. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hematopoietic progenitors
11. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells
12. Tumour necrosis factor-alpha is required for accumulation of dendritic cells in draining lymphnodes and for optimal contact sensitization
13. IL-12: A key cytokine in immune regulation
14. Inhibition of angiogenesis in vivo by interleukin 12
15. Inhibition of angiogenesis by interleukin 12 is mediated by the interferon-inducible protein 10
16. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
17. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells
18. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells
19. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
20. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules
21. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
22. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
23. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
24. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or RNA in patients with metastatic malignancies expressing CEA
25. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function
26. Induction of systemic and therapeutic anti-tumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
27. + T cells
28. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: Critical role in migration from the tumor site to draining lymph nodes
29. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors
30. IL-12 up-regulates CD40 ligand (CD154) expression on human T cells
31. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
32. + T cell immunity
33. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12
34. A comparison of gene transfer methods in human dendritic cells
35. Human dendritic cell (DC)-based anti-infective therapy: Engineering DCs to secrete functional IFN-γ and IL-12
36. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing and IFN-α
37. Applications of retrovirus-mediated expression cloning